Adar Poonawalla, Serum Institute of India CEO (Dhiraj Singh/Bloomberg via Getty Images)

Covid-19 roundup: Serum In­sti­tute eyes Africa for glob­al ex­pan­sion — re­port; Jun­shi an­tivi­ral hits pri­ma­ry end­point in late-stage tri­al

Af­ter Serum In­sti­tute CEO Adar Poon­awal­la an­nounced last month that the world’s largest vac­cine mak­er stopped pro­duc­ing dos­es of Covid-19 vac­cines back in De­cem­ber, the in­sti­tute is look­ing to ex­pand.

The CEO told Reuters Mon­day that the com­pa­ny is con­sid­er­ing es­tab­lish­ing its first man­u­fac­tur­ing plant in Africa in its next step to­ward glob­al ex­pan­sion af­ter suc­cess­ful­ly mass pro­duc­ing and sell­ing hun­dreds of mil­lions of Covid-19 vac­cine dos­es out of its In­dia-based fa­cil­i­ties.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.